Calcitonin and calcitonin receptors by Masi, Laura & Brandi, Maria Luisa
Laura Masi
Maria Luisa Brandi
Regional Center for Hereditary Endocrine Tumors
Department of Internal Medicine, University of Florence, 
Florence, Italy
Address for correspondence: 
Maria Luisa Brandi, M.D., Ph.D.
Regional Center for Hereditary Endocrine Tumors
Department of Internal Medicine
University of Florence
Viale Pieraccini 6, 50139 Florence, Italy
Ph. +39 055 4296586
Fax +39 055 4296585
E-mail: m.brandi@dmi.unifi.it
Summary
Calcitonin (CT) is a polypeptide hormone with 32 aminoacids
syntetized primarily by the thyroid. 
Several evidences support the existence of nonthyroidal CT like
peptide. The CT gene transcript also encodes a distinct peptide
known as calcitonin gene related peptide (CGRP) which is a po-
tent vasodilator and responsible for the stimulation of the
glomerular filtration rate. In addition, a 37 aminoacid peptide
amylin has been originally isolated by pancreatic β-cells.
Amylin is able to inhibit insulin secretion, glucose transport in-
to the skeletal musculature and gluconeogenesis. It is also able
to inhibit gastric emptying. In the kidney it is able to modulate
Calcium (Ca2+) excretion and increases renin activity. Finally,
high affinity amylin receptors have been identified in the brain
of the rat. The calcitonin receptor (CTR) is a member of a sub-
family of the seven-transmembrane domain G-protein coupled
receptor super family that includes several peptides. Members
of this family have a similar structure with other seven-mem-
brane-spanning domain G-protein coupled receptors. 
The genetic contribution to osteoporosis susceptibility is well
documented and many studies demonstrated that genetic fac-
tors play important roles in the regulation of bone metabo-
lism. Restriction Fragment Length Polymorphisms (RFLPs) for
the CTR gene have been described in the literature with a pos-
itive association with the lumbar bone mineral density (BMD),
femoral neck BMD and with a lower incidence of vertebral
fractures.
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Calcitonin
The calcitonin (CT) is a polypeptide hormone first discovered
by Coop and colleagues in the course of investigations to iden-
tify hormones that regulate serum levels of calcium (1). CT is
able to decrease blood calcium levels by direct inhibition of me-
diated bone resorption and by enhancing calcium excretion by
the kidney (2, 3). Human CT is a single-chain peptide of 32-
aminoacid residues. The molecular mass of the hormone is
3418 Da. There is a disulfile bridge connecting the cysteines at
position 1 and 7 to form a 7 amino-acid ring structure at the
amino terminus. The precursor of CT, pre-procalcitonin (Pre-
ProCT) contains 141 aminoacids (4).
Several evidences support the existence of non-thyroidal CT-
like peptide. Indeed, Davis et al. (5) demonstrated that prostate
gland was able to produce a large amount of CT. In addition,
CT is present in the central nervous system (6). The protein se-
quence for the CT has been determined in several species. It is
highly conserved within the N-terminal loop region but demon-
strates divergence in the rest of the sequence (7). The mature
human CT originates from the calcitonin-I (CALC-I) gene on
chromosome 11. The CT gene family consists of four known
genes (CALC-I to CALC-IV) that contain nucleotide sequence
homologies (8). CALC-I is the only gene that produces CT.
However, both CALC-I and CALC-II genes produce the hor-
mones CT gene-related peptide type I and II (CGRP-I and II).
The CALC-III is able to produce both CT and CGRP and finally
CALC-IV produces amylin (Fig. 1) (8). 
The biosynthetic secretory pathway for CT involves a complex
series of progressive modifications: after the biosynthesis and
folding of ProCT, subsequent proteolytic processing occurs
both within the Golgi apparatus (9) and later within the secreto-
ry granules. It is likely that the cleavage of ProCT and conse-
quent immature CT could be due to the action of a prohormone
convertase enzymes (PCs). During early posttranscriptional
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Figure 1 - The human calcitonin gene family. 
a. Human CALC-I gene
b. Human CALC-II gene
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c. Human CALC-III gene d. Human CALC-IV (amylin) gene
processing, the nProCT segment may act as a signal for sort-
ing its parent ProCT molecule to the nascent secretory vesicle
of the regulatory pathway. Here, the prohormone undergoes
further proteolytic cleavage to release CT (8). Chromogranin B
may function as a helper protein to favor trans-Golgi sorting to
the regulated secretory pathway (10). Within the newly formed
secretion vesicles, the proteolytic cleavage releases immature
CT. Then, as amidation proceeds, mature CT is produced and
is progressively concentrated within the secretory vesicles (Fig.
2) (8, 11). 
The biologically relevant effects of the CT appear in bone,
kidney, central nervous system, respiratory tract and gas-
trointestinal and reproductive systems. Mature CT plays an
important role in skeletal homeostasis, being a key modulator
of bone resorption (8). It acts directly on osteoclast calcitonin
receptor to inhibit bone resorption (1). The hormone inhibits
bone resorption by inducing an acute quiescence of cell
motility.
The physiological actions of CT are mediated primarily by the
ability of its receptor to couple to at least two signal transduc-
tion pathways. 
Calcitonin-related peptide
CT is initially synthesized as a precursor containing 136
aminoacids and a leader sequence at its amino terminal re-
gion. The leader sequence is cleaved during transport of CT to
the endoplasmic reticulum. The CT gene transcript also en-
codes a distinct peptide known as calcitonin gene-related pep-
tide (CGRP). It is a potent vasodilator and responsible for the
stimulation of the glomerular filtration rate (12). The tissue
specificity of this trancript is regulated by alternative splicing of
the CT gene (13). The pre-RNA of the CT/CGRP gene contain
six exons and can be processed in two way with a regulatory
event in the processing choice with inclusion or exclusion of
the alternative 3’ terminal exon 4. In particular, in parafollicular
cells of the thyroid, 95% of the CT/CGRP pre-RNA is
processed to include exon 4 followed by polyadenylation in or-
der to produce CT. In the brain, 99% of the CT/CGRP pre-RNA
is processed to exclude the exon 4 and include exon 5 and 6
with usage of the exon 6 polyadenylation site to produce
CGRP (7, 13). 
In addition, a 37 aminoacid peptide amylin has been originally
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Figure 2 - The biosynthetic secretory pathway for CT. ProCT (ProCalcitonin) is cleaved into the Golgi apparatus by the action of a prohormone con-
vertase enzymes (PCs). Consequently immature CT (iCT) present in the secretory vesicle, undergoes further proteolytic cleavage to release mature
CT (mCT). Chromogranin B may function as a helper protein to favor trans-Golgi sorting to the regulated secretory pathway.
isolated by pancreatic β-cells (14). Calcitonin gene-related pep-
tide (CGRP) and amylin are homologous 37 aminoacid pep-
tides the gene for which probably has a common ancestral ori-
gin. Amylin is able to inhibit insulin secretion, glucose transport
into the skeletal musculature and gluconeogenesis (7). In addi-
tion, amylin is able to inhibit gastric emptying. In the kidney it is
able to modulate calcium (Ca2+) excretion and increases renin
activity (15, 16). Finally, high affinity amylin receptors have
been identified in the brain of the rat (17). 
Amylin and CGRP have comparable effects. In skeletal muscle
the primary effects are the inhibition of glycogen synthesis and
stimulation of glycogenolysis with a reduction of glucose up-
take and increased glycolisis. In the liver they stimulate the glu-
cose output as a result of gluconeogenesis. By these ways
amylin and CGRP act as noncompetitive antagonist of insulin
and produce insulin resistance (19). In addition CGRP is potent
vasodilatator and its receptors are distributed throughout the
vascular system. CGRP is also an abundant peptide in the ner-
vous system suggesting a neuromodulatory role. Amylin and
CGRP increase renin sectretion. CGRP is also able to inhibit
bone resorption. There is also evidence that CGRP may act on
osteoclast precursors (20). Amylin has a similar effect but only
at 100 fold higher concentrations. On the other hand, animal
studies demonstrated that both amylin and CGRP are able to
stimulate the osteoblast activity (18). However, what role
amylin and CGRP play in normal bone metabolism and bone
pathology remains to be determined. The effects of both amylin
and CGRP are, broadly, to increase bone formation and re-
duce bone resorption. The most recently discovered member
of the calcitonin peptide family is the adrenomedullin (AM). It
has been isolated for the first time from a human phecromocy-
toma and it is expressed in the adrenal medulla (20). It is clear
that either activation or disruption of AM signaling might con-
tribute to many pathological conditions including hypertension,
congestive heart failure, pulmonary hypertension, neoplastic
growth, and inflammatory diseases (21). 
Calcitonin receptors
The activities of CT are mediated by high affinity calcitonin re-
ceptors (CTRs). The CTR is a member of a subfamily of the
seven-transmembrane domain G-protein coupled receptor su-
perfamily that includes several peptides. Members of this fami-
ly have a similar structure with other seven-membrane-span-
ning domain G-protein coupled receptors. Lin et al. cloned the
porcine CTR (pCTR) cDNA for the first time in 1991 (22). This
receptor was characterized by a long NH2-terminal domain that
was extracellular. It was similar to parathyroid/parathyroid hor-
mone-related peptide receptor and the secretin receptor (7).
Subsequent cloning of the pCTR gene demonstrated it is ap-
proximately 70 kb in length and contains at least 14 exons, 12
of which encode the protein. The human CTR was cloned from
an ovarian carcinoma cell line (BIN-67) (23). Different isoforms
of CTR resulting from alternative splicing of the gene have
been described in various animal species with differential tis-
sue expression transcripts (24) and different signaling proper-
ties (25). Two different isoforms have been described in human
giant cell tumor of bone (26). The first isoform, designed as
GC-10, differs from the previously described ovarian-human
CTR gene (26) in the 5’-region in that it lacks a 71-bp segment,
while being almost identical in the 3’-region. The second hu-
man giant cell tumor-CTR cDNA variant, indicated as GC-2,
lacks 71-bp 5’ insert but also 48 nucleotides encoding part of
the first intracellular domain (26). It is likely that differential ex-
pression of CTR isoforms could be a mechanism of regulation
of biological responses to CT. Shift in the predominant CTR
isoform(s) could in part explain the variable responsiveness to
CT in patients with high turnover metabolic bone disease (26).
The CTR gene has been mapped to chromosome 7q21.3 (27).
Calcitonin and cell signalling
The principal mechanism of action of CT it due to the ability of
its receptor to couple at least two signal transduction pathways.
One of the most important pathways is coupled with the cAMP
signal transduction. However, CTRs can also couple to the
phospholipase C (PLC) enzyme pathway. The PLC pathway,
as with the cAMP pathway, can be initiated by the coupling of
receptors to multiple G-proteins. Activation of the PLC causes
the release of Ca2+ from intracellular stores and promotes an
influx of external calcium (7). 
In addition, CTRs are able to activate the phospholipase D
(PLD) (7). Finally, Chen et al. demonstrated that CT when




Osteoclasts are the major target for the action of CT. It is able
to interfere with osteoclast differentiation from precursor cells
and fusion of mononucleated precursors to form multinucleated
cells in bone marrow cultures (29). CT plays an important role
in skeletal homeostasis, being a key modulator on bone re-
sorption (8). It acts directly on CTRs to inhibit bone resorption
by inducing contraction and inhibits osteoclast motility (Q ef-
fect) occurring within 1 min and this is followed by a more grad-
ual retraction of the osteoclasts (R effect) (7, 8, 30). Both
cAMP and intracellular calcium (Ca2+) are second messengers
for the Q and R effects, and both are G-protein mediated (8).
CT inhibits also other components of the osteoclast, such as
the release of acid phosphatase and the expression of carbon-
ic anhydrase II (31, 32).
Kidney
The kidney is the principal site of CT degradation by neutral
endopeptidase (NEP) (8). In normal men the effect of CT on
the kidney is to stimulate diuresis and increases the fractional
excretion rate of sodium and chloride. In addition, in urine a
calcium and phosphate excretion increases. In hypercalcemic
patients with metastatic bone disease, the administration of CT
induces a rapid fall in serum calcium due primarily to inhibition
of renal tubular reabsorption (7).
Central nervous system
CT has specific binding sites within the central nervous system.
The intracerebral injection of CT suppresses food and water in-
take in rats (33). In the human, large doses of salmon CT re-
duce the serum concentrations of testosterone, LH and FSH
probably acting via hypothalamic level (8, 34) and the chronic
administration to humans with migraine headaches increases
the levels of β-endhorfin, as well as ACTH and cortisol (8). 
Breast cancer cell lines
It is known that cell proliferation was inhibited when human
breast cancer cells in culture were treated with CT (35, 36). Au-
toradiographic and radioligand-binding techniques with iodinat-
ed CT have identified high-affinity CTRs in the human breast
cancer cell lines T47D and MCF-7 (36). In a recent study Wang
et al. have demonstrated that CTR mRNA is constantly ex-
pressed in normal ductal epithelium and in breast cancer. In
addition a decrease of CTR expression was found more often
in cases with lymph node metastasis suggesting that CTR
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might be of great potential significance in breast cancer pro-
gression (36). 
Gastrointestinal system 
In human, CT increases gastric acid and pepsin secretion and
decreases pancreatic amylase and pancreatic polypeptide. At
high concentrations, CT increases the net secretion of water
and electrolytes form the human jejunum and ileum, and has
been postulated that these effects may explain the presence of
diarrhea seen in some patients affected by medullary thyroid
carcinoma (8).
Reproductive system  
Sperm contain a very high concentration of CT which is about
40 times that found in the serum. In vitro experiments showed
that CT likely acts as an endogenous regulator of sperm fertiliz-
ing ability in vivo (7, 37). In addition, CT occurs in both the
uterus and placenta. The intraplacental presence of CT recep-
tors, suggest a role of CT in the regulation of placental func-
tion; however, small studies evaluated this possibility (8). 
Respiratory system
9CT is found within the pulmonary neuroendocrine (PNE) cells,
which are situated near the basement membrane and often ex-
tend to the lumen of the airway (8). CT affects transcellular and
intracellular movements of calcium, and hence may exert and in-
trapulmonary paracrine action. In fact, CT is able to inhibit
prostaglandin and thromboxane secretion (8) and increases the
cartilagineous growth (8). Finally, CT blocks the bronchoconstric-
tor effects of bombesin-like peptides and substance P. 
Calcitonin receptor polymorphisms and osteoporosis
Osteoporosis is a common skeletal disease characterized by
an excessively fragile skeleton and susceptibility to fracture
(38). It is a multifactorial disease and several environmental
and genetic factors play an important role. The genetic contri-
bution to osteoporosis susceptibility is well documented and
many studies demonstrated that genetic factors play important
roles in determining population variation of Bone Mineral Den-
sity (BMD) (39), bone quality (40), and osteoporotic fractures
(41, 42). The genes that regulate BMD and bone fragility are
potentially important targets for the design of new drugs that
can be used to treat bone disease. Genetic markers will also
be used as diagnostic tools in the assessment of individuals at
risk of developing osteoporotic fractures and could be used to
help target preventive therapies to those individuals who are at
risk of fracture. In addition, genetic profiling could be useful to
distinguish treatment responders from non-responders and to
identify patients who might be at risk of developing unwanted
side effects. 
One of the gene that can be involved in this process is the CTR
gene. A Restriction Fragment Length Polymorphism (RFLP) for
the CTR gene has been for the first time described in 1998 us-
ing Taq I endonuclease (43). The authors found a positive as-
sociation between this polymorphism and lumbar spine bone
mineral density (LS-BMD). However, no significant variation of
BMD among the genotypes was observed in the femoral neck
BMD (43). In addition, Nakamura et al. described a polymor-
phic site at the CTR gene by Alu I restriction enzyme at the
1377th nucleotide expressing either proline (CC genotype) or
leucine (TT genotype) (44). They observed that in the Japan-
ese population the most represented CTR was the CC geno-
type and the less represented was the TT genotype. Converse-
ly in the Italian population the TC and TT allelic variants repre-
sented the most frequent genotypes, underlying the importance
of ethnic origin as a variable that should be always taken in
consideration (45). In addition, Duncan's test used to compare
the genotypes showed that TT genotype has significant lower
lumbar BMD in comparison with CC genotype (Fig. 3).
Taboulet et al. studied the distribution of these alleles in a co-
hort of 215 postmenopausal Caucasian women suffering or not
from osteoporotic fractures. They found that Rr genotype (the
TC genotype indicated by Masi et al. and Nakamura et al.) was
associated with a higher femoral neck BMD in comparison with
RR and rr genotypes. In addition Rr genotype was associated
with a lower incidence of vertebral fractures (46). The authors
emphasize the importance of the high conservation of the pro-
line residue in all species studied with the exception of the hu-
man isoforms. The absence of the proline residue could alter
the secondary structure of the calcitonin receptor, more so as
two other proline residues border this region. Progressive trun-
cation of the C-terminal tail of the porcine receptor complex re-
duced the magnitude of adenylate cyclase responses (47).
This underlines the importance of the CTR C-terminal domain
and suggests that proline/leucine mutation could alter receptor
biological activity (46). In addition, heterozygotes could pro-
duce both alleles of the receptor, resulting in advantage as
compared with homozygotes, especially as this genetic effect
accounts for 13% of the total variance of BMD in covariance
analysis (46). Recently, this polymorphism has been studied in
a group of postmenopausal women in Taiwan (48) confirming
the association between TT genotype and low bone mineral
density at the lumbar spine and femoral neck. A lower lumbar
spine BMD was also found in subjects with TT genotype affect-
ed by Juvenile Idiopathic Arthritis (49).
A complete polymorphism scan of the human calcitonin recep-
tor gene identified 11 polymorphic sites in the gene and con-
firmed the presence of the previously identified nucleotide
T1340C (codon 447) polymorphism. Because a leucine to pro-
line change has the potential for significant structural alteration,
receptor genes encoding either leucine or proline at residue
447 were transiently expressed in COS-7 cells to determinate
the binding and functional consequences of this polymorphism.
The presence of this SNP (single nucleotide polymorphism) ap-
pears to have no statistically significant difference with the re-
ceptor’s ability to bind CT or signal when activated with the hor-
mone (50). A study conducted in Italian men found that CC
genotype was associated with lower BMD and with lower level
of bone alkaline phosphatase and estradiol in comparison with
TT genotype suggesting a depression of bone formation in
these subjects (51). A correlation between CTR polymorphism
and buccal margin bone loss has been observed in subjects
undergoing to implants on maxillae and mandibles (52) and fi-
nally the CTR polymorphism has been indicated as an impor-
tant genetic marker for severe periodontitis (53).
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Figure 3 - Lumbar BMD values according to CTR genotypes. TT geno-
type had a significant lower lumbar BMD in comparison with CC geno-


















Recently a functional role of CTR polymorphism has been ob-
served by Zofkaova et al. (54). In particular, the authors postu-
lated that the 3β-hydroxysteroid dehydrogenase activity could
be associated with C allele at least in C19 steroids. However,
these data were observed in a relatively small number of post-
menopausal women and need confirm (54).
Research has recently begun to clarify the genes and genetic
variants that predispose to osteoporosis and regulation of bone
mass. CTR polymorphism together with other genes could be
associated with the identification of genetic markers for assess-
ment of fracture risk and the identification of novel molecular
targets for the design of drugs that can be used to treat bone
disease.
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